netFormulary NHS
NHS NEL
Demonstration Formulary
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

 

 

 
Chapter Links...
Link   NICE NG28: Type 2 diabetes in adults: management
Link   DVLA guidance
Link   NICE Guidance on prescribing
 Details...
06.06.02  Expand sub section  Bisphosphonates and other drugs affecting bone metabolism
 link Link    NICE TA160: Osteoporosis - Primary Prevention
 link Link    NOGG Osteoporosis - information for patients
 link Link    NOGG Osteoporosis Clinical Guideline Executive Summary
 link Link    NOGG Pocket Guide for Heathcare Professionals - Osteoporosis
 link Link    NICE TA160: Osteoporosis - primary prevention
 link Link    NICE TA161: Osteoporosis - secondary prevention (including strontium ranelate)
 link Link    NICE TA464: Bisphosphonates for treating osteoporosis
06.06.02  Expand sub section  Bisphosphonates
Alendronic acid (Binosto®)
(effervescent tablets)
View adult BNF View SPC online View childrens BNF 		Third Choice
Green
High Cost Medicine 		 
Link  MHRA: Bisphosphonates: atypical femoral fractures
Link  NICE TA464:Bisphosphonates for treating osteoporosis
 
Etidronate disodium
(tablets)
View adult BNF View SPC online View childrens BNF 		Formulary
Green

In line with NICE

 
Link  MHRA; Bisphosphonates: atypical femoral fractures
Link  NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Link  NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
 
 link Link    UKMI Q&A: Proton pump inhibitor interaction with bisphosphonates? -
06.06.02  Expand sub section  Denosumab
06.06.02  Expand sub section  Strontium renelate
 ....
 Non Formulary Items
Alendronic Acid
(Oral solution)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Black

Removed from formulary in Decemeber 2016, replaced by effervescent tablets
Alendronic Acid  (Fosamax®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Alendronic Acid  (Fosamax® Once Weekly)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Alendronic Acid with colecalciferol  (Fosavance®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Disodium Eitdronate  (Didronel PMO®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Risedronate Sodium  (Actonel®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Black

Actonel - Black

RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL - Black

RISEDRONATE/CALCIUM CARBONATE/COLECALCIFEROL / Actonel Combi - Black

 
Link  UKMI Q&A: Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
Link  MHRA: Bisphosphonates: atypical femoral fractures
Link  NICE TA464: Bisphosphonates for treating osteoporosis
Link  TA 161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
Link  TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
Tiludronic Acid  (Skelid®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
  
Key
Restricted Drug Restricted Drug
Unlicensed Drug Unlicensed
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
ICB
 ICB
Green Low Carbon

Low carbon footprint
Amber Medium Carbon

Medium carbon footprint
Red High carbon footprint

High carbon footprint
Status Description

Green

 Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications  

Amber Initiation

 Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.  

Amber SC

 Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.  

Amber Recommended

 Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.  

Red

 Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only  

Grey

 Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.  

Black

 Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.  

Multiple

 Check Notes as varies across the area  

netFormulary